Abstract
We have previously reported on the decrease of the microviscosity after IA T4 treatment suggesting enhancement of lung maturity. In the present study we report on the outcome of non-selected 856 pregnancies in 4 groups of patients. (1) No treatment; (2) intra-amnotic T4 500 ug (1 to 3 injections, a week apart); (3) betamethasone (B) (1 to 4 courses); and (4) combined IA T4 + B. There was no significant difference in the age and weight at birth in the 4 groups.
There was no significant difference in the incidence of RDS or the mortality from RDS between the 4 groups; there was a significant difference (p < 0.05) in the overall mortality (*after congenital letal malformation were excluded). These data suggest that: (1) T4 and/or betamethasone therapy may decrease RDS and non-RDS related mortality and (2) the intra-amnotic route of T4 represents a safe, effective method of hormone administration. This approach deserves further investigation as a tool to help us understand and treat fetal abnormalities during the intrauterine period.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sack, J., Feldman, J., Barkai, G. et al. 1504 Intra amniotic thyroxine (IA T4) In the prevention of RDS. Pediatr Res 19, 361 (1985). https://doi.org/10.1203/00006450-198504000-01528
Issue date:
DOI: https://doi.org/10.1203/00006450-198504000-01528
